Form 8-K - Current report:
SEC Accession No. 0001558370-25-007060
Filing Date
2025-05-09
Accepted
2025-05-09 06:57:27
Documents
14
Period of Report
2025-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20250509x8k.htm   iXBRL 8-K 40136
2 EX-99.1 plx-20250509xex99d1.htm EX-99.1 143691
  Complete submission text file 0001558370-25-007060.txt   320638

Data Files

Seq Description Document Type Size
3 EX-101.SCH plx-20250509.xsd EX-101.SCH 3631
4 EX-101.LAB plx-20250509_lab.xml EX-101.LAB 16015
5 EX-101.PRE plx-20250509_pre.xml EX-101.PRE 10760
16 EXTRACTED XBRL INSTANCE DOCUMENT plx-20250509x8k_htm.xml XML 4816
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 25928302
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)